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Implications for Biomedical HIV Prevention
Ingrid Young*, Jessica Li, Lisa McDaid
Social and Public Health Sciences Unit, Medical Research Council, Glasgow, United Kingdom
Abstract
Objectives: To investigate the awareness of, and willingness to use, HIV Pre-Exposure Prophylaxis (PrEP), and willingness to
take part in a PrEP study among gay and bisexual men in Scotland.
Methods: Cross-sectional survey of 17 gay commercial venues in Glasgow and Edinburgh in May 2011 (N = 1515, 65.2%
response rate); 1393 are included in the analyses.
Results: Just under one-third of participants had heard of PrEP (n = 434; 31.2%), with awareness associated with being aged
older than 35 years, talking to UAI partners about HIV, and with having had an HIV or STI test in the previous 12 months.
Around half were willing to take part in a PrEP study (n = 695; 49.9%) or to take PrEP on a daily basis (n = 756; 54.3%). In
multivariate analysis, willingness to take PrEP was associated with lower levels of education, regular gay scene attendance,
‘high-risk’ unprotected anal intercourse (UAI) and testing for HIV or STI in the previous 12 months. Reasons for not wanting
to participate in a PrEP study or take PrEP included perceptions of low personal risk of HIV and concerns with using
medication as an HIV prevention method.
Conclusions: There is a willingness to engage in new forms of HIV prevention and research amongst a significant number of
gay and bisexual men in Scotland. Future biomedical HIV interventions need to consider the links between sexual risk
behaviour, testing, and potential PrEP use.
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Introduction
Recent research has demonstrated that prescribing antiretrovi-
rals (ARVs) to HIV negative people before sexual exposure to HIV
can help reduce HIV transmission. iPrEX demonstrated a 44%
reduction in the acquisition of HIV amongst serodiscordant men
who have sex with men (MSM) in couples when using Pre-
exposure Prophylaxis (PrEP) [1]. The Partners Prevention study
subsequently demonstrated a reduction of up to 75% amongst
serodiscordant heterosexual couples [2]. The US Food and Drug
Administration (FDA) approved the use of Truvada (emtricita-
bine/tenofovir disoproxil fumarate) for use as PrEP in July 2012,
[3] and the Center for Disease Control (CDC) has issued interim
guidance for both MSM and for heterosexual serodiscordant
couples [4,5]. Although there is still much debate around the
efficacy and safety of PrEP, [6] the recent FDA decision to expand
the indications for Truvada use in the United States has
introduced a significant new biomedical option into HIV
prevention. In the UK, PrEP is currently not regulated for use.
Recent guidelines from the British HIV Association (BHIVA) have
urged caution, given mixed findings from other PrEP trials, and
further evidence that PrEP is effective and appropriate for HIV
prevention in the UK is being sought [6].
MSM have been identified as a high-risk group for which PrEP
may be an appropriate prevention option. There has been growth
in recent research examining attitudes, awareness and willingness
to use PrEP among MSM primarily in the US, [7,8,9,10,11,12]
with more limited research in Australia, China, France, Thailand
and Canada [13,14,15,16,17]. To date, only one peer-reviewed
study with MSM in the UK has been published, [18] although
preliminary findings from a few UK studies have been reported
[19,20]. Most of these studies show very low levels of awareness of
PrEP amongst MSM, but a relatively high level of willingness to
use PrEP as part of an HIV prevention strategy. Although findings
from these community survey studies cannot predict actual, future
behaviour, they have revealed significant proportions of MSM
who would consider using PrEP if available. This paper presents
findings from the 2011 Medical Research Council (MRC) Gay
Men’s Sexual Health Survey around attitudes towards PrEP
amongst gay and bisexual men in Scotland. We examine the
factors associated with awareness of, and the likelihood of taking,
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e64038
PrEP and consider the implications for future PrEP and HIV
prevention research.
Methods
The MRC Gay Men’s Sexual Health Survey collected
anonymous, self-complete questionnaires and oral fluid specimens
(collected with OraSureH Oral Specimen Collection Devices,
OraSure Technologies, Inc, Bethlehem, PA) in 17 gay commercial
venues (15 bars and 2 saunas) in Glasgow and Edinburgh in May
2011. A form of time and location sampling was used to recruit
representative samples of MSM [21]. A team of temporary
fieldworkers was trained then employed to distribute and collect
questionnaires at two different time points in the early (19.00–
21.00) and late evening (21.00–23.00). No bar was visited twice in
the same evening. At the end of the survey each bar had been
visited at both time points on each day of the week. Each sauna
was visited six times over the course of the two week survey period;
for a two hour period between 17:00–19:00 on Thursdays and
between 14:00–17:00 on Saturdays and Sundays. A total of 2325
eligible men were approached and 1515 participated in the survey
(65.2% response rate [RR]); 1218 provided oral fluid samples
(52.4% RR). Among the men who declined to participate,
temporary fieldworkers estimated that 28.6% were aged ,30
years, 26.7% were aged 30–39 years, and 35.9% were aged 40+
years, which suggests non-participants were considerably older
than men who chose to participate in the survey; 20.3% were
alone in the venue at the time, 37.6% were with one other person,
and 33.5% were part of a larger group. Ethical approval was
granted by University of Glasgow College of Social Sciences Ethics
Committee.
Questionnaires included demographics (age, area of residence,
education, frequency of gay scene use), sexual health (HIV/STI
testing), and sexual behaviour in the previous 12 months. HIV
treatment optimism was measured via agreement with the
statement ‘I am less worried about HIV infection now that
treatments have improved’ (5 point Likert scale strongly agree to
strongly disagree). A measure of unprotected anal intercourse
(UAI), which presented a higher risk of HIV infection, was created
and includes men who reported any of the three following
behaviours: UAI with 2 or more partners, UAI with casual
partners, and/or UAI with unknown/discordant partners in the
previous 12 months.
A brief description of PrEP was provided: Researchers are testing
pre-exposure prophylaxis (PrEP) – taking antiretroviral pills daily to help
prevent HIV in HIV-uninfected people at high risk. This is different from PEP
which is taken AFTER exposure. Men were asked about their
awareness of PrEP (response: yes, no or don’t know), their
willingness to take part in a PrEP research study (response: yes, no
or don’t know), and their likelihood of taking PrEP on a daily basis
if it were to become available (response: 5 point Likert scale very
likely to very unlikely). Responses for awareness were recoded into
two categories: had not/did not know if heard of PrEP and heard
of PrEP. Responses for willingness to be a part of a research study
on PrEP were recoded into uncertain/unwilling to take part in
study and willing to take part in study, and responses for likelihood
of using PrEP on a daily basis were recoded into unlikely/
uncertain to use PrEP (very unlikely, unlikely, and uncertain
combined) and likely to use PrEP (very likely and likely combined).
If participants reported being uncertain or unwilling/unlikely to
take part in a PrEP research study or to take PrEP on a daily basis,
they were given the opportunity to answer an open ended question
asking their reason for their response.
Data were analysed using SPSS 15.0 for Windows. Men who
tested HIV-positive from the study using the OraSureH test and
were aware of their status (n = 44) and men who had missing data
on any outcome variables (n = 78) were excluded from the
analyses, leaving a sample of 1393 men. This included 1108
HIV-negative men, 13 undiagnosed HIV-positive men, and 272
men who did not provide oral fluid samples (of whom, 228
reported ever HIV testing with 211 reporting the result to be HIV-
negative and only 9 reported being HIV-positive). Chi-square tests
were used for bivariate comparisons. Variables significant at the
bivariate level (p,0.05) were entered into three logistic regression
models used to estimate odds ratios (OR) and 95% confidence
intervals (CI) for awareness of PrEP, willingness to participate in a
PrEP research study, and likelihood of using PrEP on a daily basis.
A thematic analysis was used to examine reasons for reporting
uncertainty or unwillingness to take part in a research study on
PrEP or to use it on a daily basis. A total of 180 men provided
short, open-ended reasons for why they were uncertain or
unwilling to taking part in a study, and 195 men reported reasons
for being uncertain or unlikely to take PrEP on a daily basis. All of
the responses were analysed. The first author (IY) coded these
short answers using an inductive approach and grouped them
according to themes that emerged from the data. The second
author (JL) confirmed the codings and groupings for accuracy and
consistency [22,23,24].
Results
Sample Characteristics
The characteristics of the sample are shown in Table 1. The
mean age of men sampled was 32.8 years (range 18–83,
SD=10.88) and nearly half had degree or postgraduate level
education. The majority were frequent visitors of the gay scene.
One–third reported having any higher risk UAI in the previous 12
months and 27.6% had always or sometimes talked to their yearly
UAI partners about HIV. More than half had had a recent HIV or
STI test and the majority were uncertain or not optimistic about
HIV treatment.
Awareness and Willingness to use PrEP
Four hundred and thirty four men (31.2%) had heard of PrEP.
Half of the men sampled were willing to take part in a research
study on PrEP; a little more than one quarter did not want to and
a little more than one fifth did not know if they would want to take
part in a PrEP study. Similar results were reported for the
likelihood of using PrEP on a daily basis to prevent HIV infection.
Half of men sampled reported being likely to take it on a daily
basis, while one quarter was uncertain and one fifth reported being
unlikely to use it (Table 1). Willingness to take part in a PrEP
research study and likelihood of using PrEP were highly
associated. Among men who reported they would be unwilling
to take part in a research study, 66.9% (n= 467) also reported that
they would be unlikely to use PrEP on a daily basis (x2 = 252.80,
p,0.001).
Factors Associated with Awareness and Willingness to
use PrEP
Tables 2, 3 and 4 show the factors associated with awareness of
PrEP, willingness to participate in a PrEP research study and
likelihood of using PrEP on a daily basis. When controlling for the
factors significant at the bivariate level in multivariate logistic
regression, the odds of having heard of PrEP remained signifi-
cantly higher for men aged 36+ compared to men aged 18–25,
men who always or sometimes talked to their UAI partners about
PrEP Acceptability amongst MSM in Scotland
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HIV compared to men who never did so, and men who had an
HIV or STI test in the previous 12 months compared to those who
did not (Table 2). The adjusted odds of being willing to participate
in a research study remained significantly higher for men who
visited the gay scene once or more a week compared to men who
visited once a month or less, and for men who had heard of PrEP;
the odds remained significantly lower for men who resided outside
of Scotland than within Scottish areas and men who were
uncertain or not optimistic about HIV treatment (Table 3). The
adjusted odds of being likely to use PrEP on a daily basis were
higher for men who had secondary or further/vocational level
education compared to degree or postgraduate level education,
visited the gay scene at least 2–3 times a month or more compared
to once a month or less, reported any higher-risk UAI, had an
HIV or STI test in the previous 12 months, and had heard of
PrEP; the odds remained lower for men who were aged 26+
compared to men aged 18–25, men who resided within Edinburgh
compared with elsewhere in Scotland, other than Glasgow, and
men who were uncertain or not optimistic about HIV treatment
(Table 4).
Reasons given for not Participating in a PrEP Study
Out of the 698 men who reported being unlikely or uncertain
about participating in a PrEP study, 180 men (25.8%) supplied a
reason in response to the open-ended question. One-quarter
(n = 46) described themselves as being at low risk of HIV because
of: being in a long-term, stable and/or monogamous sexual
relationship; practicing safer sex; or having limited numbers of
sexual partners. Of these men, 89.1% (n= 41) reported no higher-
risk UAI in the previous 12 months. One-quarter (n = 45) cited
concerns with using medication for HIV prevention and a further
one-quarter (n = 41) reported not being interested in participating
in a trial. Other reasons included: there not being enough
information available on PrEP (n= 12); anxieties around privacy
and/or embarrassment (n = 9); or concerns that PrEP might
encourage irresponsible behaviour (n = 4).
Reasons given for being Unlikely to use PrEP
Of the 637 men who reported being unlikely or uncertain about
using PrEP, 195 men (30.6%) supplied a reason for this. Over half
(n = 114) reported that they did not perceive themselves to be at
risk of HIV transmission because they practiced safer sex, had
limited and/or regular sexual partners or avoided high risk sexual
acts. Of the men who answered in this way, 85.0% reported no
higher-risk UAI in the previous 12 months. Around one-quarter of
respondents (n = 51) described concerns around the medication
itself. A minority (n = 7) described concerns that PrEP may
encourage irresponsible sexual behaviour. There were no signif-
icant differences in age, other demographics, sexual risk behav-
Table 1. Sample Characteristics (N = 1393).
n %
Age
18–25 434 31.4
26–35 454 32.9
36–45 297 21.5
46+ 196 14.2
Postcode
Scottish 207 15.8
Edinburgh 439 33.5
Glasgow 587 44.8
Rest of UK 78 5.9
Qualifications
Secondary 192 14.7
Further/vocational 492 37.7
Degree/Postgraduate 622 47.6
Frequency of gay scene use
Once a month or less 411 29.7
2–3 times a month 355 25.7
Once or more a week 616 44.6
Had any higher-risk UAI*
No 918 66.6
Yes 460 33.4
Talked about HIV with UAI partners
Did not have UAI in the previous 12 months 783 56.2
Always/sometimes 385 27.6
Never 225 16.2
Had an STI in the previous 12 months
No 1214 88.3
Yes 161 11.7
Had an HIV or STI test in the previous 12 months
No 587 43.3
Yes 768 56.7
HIV treatment optimism{
Agree 278 20.1
Uncertain/disagree 1107 79.9
Heard of PrEP
Yes 434 31.2
No 832 59.7
Don’t know 127 9.1
Willingness to take part in PrEP study
Yes 695 49.9
No 393 28.2
Don’t Know 305 21.9
Likelihood of using PrEP on a daily basis
Very likely 457 32.8
Likely 299 21.5
Uncertain 356 25.6
Unlikely 188 13.5
Table 1. Cont.
n %
Very Unlikely 93 6.7
*UAI with 2 or more partners, UAI with casual partners, and/or UAI with
unknown/discordant partners in the previous 12 months.
{HIV treatment optimism – ‘I am less worried about HIV infection now that
treatments have improved’.
doi:10.1371/journal.pone.0064038.t001
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iours or sexual health between men who reported perceptions of
risk and men who reported concerns with using mediations as their
reasons for being unlikely to use PrEP (data not shown).
Discussion
This is the first study to report on awareness and willingness to
use PrEP among MSM in Scotland. We found that 31.2% of
participants had heard of PrEP, 49.9% were willing to take part in
a PrEP study and 54.3% of participants reported being likely or
very likely to take PrEP on a daily basis. These findings suggest
that there is a willingness to engage in new forms of HIV
prevention amongst a significant number of MSM in Scotland.
The levels of awareness in our sample appear to be much higher
than those reported in other studies with MSM. A Canadian study
with 195 MSM conducted in 2010 found limited knowledge
(14.1%) of PrEP [17]. A more recent online survey of MSM in the
US conducted after the release of the iPrEX findings in 2011
Table 2. Factors associated with Awareness of Pre-exposure Prophylaxis for HIV prevention (N= 1393).
Did not/Did not
know if heard of
prep (n=959),
n (%)
Heard of PrEP
(n =434),
n (%) OR 95% CI p value AOR 95% CI p value
Age
18–25 320 (73.7) 114 (26.3) 1 1
26–35 322 (70.9) 132 (29.1) 1.15 (0.86–1.55) 0.350 1.13 (0.83–1.54) 0.425
36–45 180 (60.6) 117 (39.4) 1.83 (1.33–2.50) ,0.001 1.89 (1.35–2.63) ,0.001
46+ 129 (65.8) 67 (34.2) 1.46 (1.01–2.10) 0.043 1.52 (1.03–2.24) 0.034
Postcode
Scottish 148 (71.5) 59 (28.5) 1
Edinburgh 298 (67.9) 141 (32.1) 1.19 (0.83–1.71) 0.354
Glasgow 403 (68.7) 184 (31.3) 1.15 (0.81–1.62) 0.445
Rest of UK 50 (64.1) 28 (35.9) 1.41 (0.81–2.44) 0.228
Qualifications
Secondary 140 (72.9) 52 (27.1) 0.69 (0.48–0.99) 0.045 0.76 (0.52–1.11) 0.156
Further/vocational 350 (71.1) 142 (28.9) 0.76 (0.59–0.98) 0.033 0.81 (0.62–1.06) 0.122
Degree/Postgraduate 405 (65.1) 217 (34.9) 1 1
Frequency of gay scene use
Once a month or less 288 (70.1) 123 (29.9) 1
2–3 times a month 251 (70.7) 104 (29.3) 0.97 (0.71–1.32) 0.849
Once or more a week 412 (66.9) 204 (33.1) 1.16 (0.89–1.52) 0.282
Had any higher–risk UAI*
No 629 (68.5) 289 (31.5) 1
Yes 319 (69.3) 141 (30.7) 0.96 (0.76–1.23) 0.754
Talked about HIV with UAI partners
Did not have UAI in previous 12
months
542 (69.2) 241 (30.8) 1.31 (0.94–1.84) 0.115 1.22 (0.86–1.74) 0.262
Always/sometimes 249 (64.7) 136 (35.3) 1.61 (1.12–2.32) 0.011 1.48 (1.01–2.16) 0.043
Never 168 (74.7) 57 (25.3) 1 1
Had an STI in the previous 12
months
No 848 (69.9) 366 (30.1) 1 1
Yes 97 (60.2) 64 (39.8) 1.53 (1.09–2.15) 0.014 1.36 (0.95–1.94) 0.093
Had an HIV or STI test in the
previous 12 months
No 439 (74.8) 148 (25.2) 1 1
Yes 491 (63.9) 277 (36.1) 1.67 (1.32–2.12) ,0.001 1.67 (1.29–2.15) ,0.001
HIV treatment optimism{
Agree 199 (71.6) 79 (28.4) 1
Uncertain/disagree 754 (68.1) 353 (31.9) 1.18 (0.88–1.57) 0.264
OR=odds ratio; AOR= adjusted odds-ratio; 95% CI = 95% confidence interval.
*UAI with 2 or more partners, UAI with casual partners, and/or UAI with unknown/discordant partners in the previous 12 months.
{HIV treatment optimism 1– ‘I am less worried about HIV infection now that treatments have improved’.
doi:10.1371/journal.pone.0064038.t002
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found similarly low levels of awareness (19%), [10] and an online
survey of 1500 MSM in England in June 2011 found that 17% of
respondents were aware of PrEP [20]. Findings from this study
suggest that an increasing minority of MSM may already be aware
of PrEP, which will have policy and prevention implications.
There have been some concerns about possible use of PrEP off-
label, and the potential problems with this mismatch of knowledge
and availability of PrEP. However, a recent study found limited
off-label use of PrEP (2.2%) amongst MSM in London [18]. In
light of the 2012 FDA decision to approve the use of Truvada for
PrEP in the United States, and subsequent international media
coverage of PrEP debates, levels of PrEP awareness are likely to
increase.
Levels of willingness to use PrEP in our study were similar to
reported levels in both UK studies (52% & 52.4%) [18,20]. In
contrast, studies in the US found that 67% [25] of participants in
California and 74% [12] of participants in Boston were willing to
use PrEP while an Australian study reported only 28% willingness
[13]. This variation in levels of willingness with non-UK based
studies indicates the need to consider what factors contribute to
potential PrEP acceptability. Furthermore, the significant result for
the ‘rest of the UK’ category in the postcode variable suggests that
there could be regional variations in attitudes towards biomedical
prevention, as well as participating in such research.
Age appeared to be an important factor, as older men (36+
years) were more likely to have heard of PrEP. Although it is not
known how participants are accessing this information, the
variation in PrEP awareness between older and younger men
suggests that there may be a generational difference in how men
share and receive knowledge and access sexual health information
[26]. Age was also associated with likelihood to use PrEP, with
men aged 16–25 years being most likely to be willing to use it.
While Sigma et al [20] found no association with age and
willingness to use PrEP, Aghaizu et al [18] found that being aged
under 35 was associated with acceptability of PrEP. The difference
in associations between age groups raises a number of questions
relating to how access to sexual health information, sexual
behaviour and risk management may be affected by age. These
findings suggest the need for age-targeted education programmes
and support if PrEP is to be offered in the UK.
Men reporting HIV-related sexual risk behaviour were more
than twice as likely to report willingness to use PrEP than men who
did not and those tested for an STI and/or HIV in the last 12
months were almost 1.4 times as likely than men who had not
tested. This may indicate not only a concern with risk of STI and/
or HIV infection but also a response or management of this
particular risk. Holt et al [13] suggest that for men in their sample
who were interested in using PrEP but engaging in high-risk UAI,
PrEP could represent additional HIV prevention: as these men
were unlikely to use condoms, PrEP would at least act to reduce
the risks of HIV transmission. Although Golub et al [9] point to
mathematical models which demonstrate how an increase in risk
behaviour could offset the benefits of PrEP, Holt’s example
highlights the complexities of how PrEP might work in combina-
tion with testing for those men who are engaging in UAI. While
Holt et al’s observation is in relation to risk compensation, an area
which was not explored in our study, our findings relating to
sexual behaviour and testing practices suggest the need to think
about how men perceive and respond to risk in different ways and
that responses to risk of HIV may not always or only involve
condoms. For instance, MSM in London who had experience of
using post-exposure prophylaxis (PEP) were found to be more
willing to use PrEP [18]. In relation to future PrEP roll-out, these
findings also suggest the need for PrEP education programmes
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that are linked to HIV and STI testing, which would build on
existing knowledge and testing practices.
It is important to consider why nearly half of the men in our
survey rejected the option of PrEP. A significant proportion
reported low perceptions of risk relating to condom use, partner
selection or avoiding risky sexual behaviours. This suggests a
preference amongst some for behavioural HIV risk management
strategies, as well as the importance of if and how risk is perceived.
Table 4. Factors associated with likelihood of using Pre-exposure Prophylaxis for HIV prevention (N = 1393).
Unlikely/uncertain
to use PrEP
(n =637),
n (%)
Likely to use
PrEP
(n =756),
n (%) OR 95% CI p value AOR 95% CI p value
Age
18–25 156 (35.9) 278 (64.1) 1 1
26–35 223 (49.1) 231 (50.9) 0.58 (0.44–0.76) ,0.001 0.72 (0.54–0.96) 0.025
36–45 152 (51.2) 145 (48.8) 0.54 (0.40–0.72) ,0.001 0.67 (0.48–0.93) 0.016
46+ 101 (51.5) 95 (48.5) 0.53 (0.38–0.74) ,0.001 0.60 (0.42–0.88) 0.008
Postcode
Scottish 78 (37.7) 129 (62.3) 1 1
Edinburgh 214 (48.7) 225 (51.3) 0.64 (0.45–0.89) 0.009 0.68 (0.48–0.98) 0.041
Glasgow 262 (44.6) 325 (55.4) 0.75 (0.54–1.04) 0.083 0.79 (0.56–1.11) 0.177
Rest of UK 43 (55.1) 35 (44.9) 0.49 (0.29–0.83) 0.008 0.65 (0.37–1.13) 0.126
Qualifications
Secondary 79 (41.1) 113 (58.9) 1.63 (1.17–2.26) 0.004 1.53 (1.07–2.20) 0.020
Further/vocational 194 (39.4) 298 (60.6) 1.75 (1.38–2.22) ,0.001 1.49 (1.15–1.93) 0.003
Degree/Postgraduate 331 (53.2) 291 (46.8) 1 1
Frequency of gay scene use
Once a month or less 217 (52.8) 194 (47.2) 1 1
2–3 times a month 158 (44.5) 197 (55.5) 1.40 (1.05–1.86) 0.022 1.42 (1.05–1.92) 0.024
Once or more a week 258 (41.9) 358 (58.1) 1.55 (1.21–2.00) 0.001 1.35 (1.03–1.77) 0.029
Had any higher–risk UAI*
No 482 (52.5) 436 (47.5) 1 1
Yes 152 (33.0) 308 (67.0) 2.24 (1.77–2.83) ,0.001 2.14 (1.46–3.15) ,0.001
Talked about HIV with UAI
partners
Did not have UAI in previous 12
months
398 (50.8) 385 (49.2) 0.50 (0.37–0.69) ,0.001 1.00 (0.64–1.57) 0.992
Always/sometimes 162 (42.1) 223 (57.9) 0.72 (0.51–1.01) 0.056 0.78 (0.54–1.14) 0.197
Never 77 (34.2) 148 (65.8) 1
Had an STI in the previous 12
months
No 573 (47.2) 641 (52.8) 1 1
Yes 58 (36.0) 103 (64.0) 1.59 (1.13–2.23) 0.008 1.12 (0.77–1.63) 0.547
Had an HIV or STI test in the
previous 12 months
No 304 (51.8) 283 (48.2) 1 1
Yes 317 (41.3) 451 (58.7) 1.53 (1.23–1.90) ,0.001 1.38 (1.09–1.76) 0.008
HIV treatment optimism{
Agree 96 (34.5) 182 (65.5) 1 1
Uncertain/disagree 540 (48.8) 567 (51.2) 0.55 (0.42–0.73) ,0.001 0.57 (0.43–0.77) ,0.001
Heard of PrEP
No/Don’t know 458 (47.8) 501 (52.2) 1 1
Yes 179 (41.2) 255 (58.8) 1.30 (1.04–1.64) 0.024 1.38 (1.07–1.76) 0.012
OR=odds ratio; AOR= adjusted odds-ratio; 95% CI = 95% confidence interval.
*UAI with 2 or more partners, UAI with casual partners, and/or UAI with unknown/discordant partners in the previous 12 months.
{HIV treatment optimism – ‘I am less worried about HIV infection now that treatments have improved’.
doi:10.1371/journal.pone.0064038.t004
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As has been highlighted in PrEP trials, which failed to show
effectiveness, [27] perceptions of HIV risk play an important role
in adherence and ultimately to the effectiveness of PrEP as a
prevention method. Moreover, concerns around the use of
medication for HIV prevention suggests the need to consider
broader attitudes towards medication, health and HIV prevention
such as poor experiences or awareness of ART in HIV positive
peers and a lack of trust in the efficacy of the prevention
technology of PrEP.
This study has a number of limitations to consider. The nature
of this study means that it cannot predict actual, future behaviour
in relation to PrEP use. However, the findings do indicate that
MSM would be willing to consider using PrEP if it became
available in Scotland. Caution should be taken in generalizing the
findings beyond the survey population or to the wider population
of non-scene going MSM. The characteristics, risk behaviours,
and awareness and willingness to use PrEP among non-partici-
pants could be different from those who participated in our survey.
Men who chose not to participate appeared to be older than the
men who did participate and this, along with the fact that only
men who attended the venues surveyed have the opportunity to
participate, should be taken into consideration in the interpreta-
tion of our results. Findings also relied on self-report data which
could be subject to self-report bias. However, it is hoped that the
anonymous, self-complete nature of the survey limited the
potential of this. In addition, the men were asked about their
willingness to use a technology they knew little about. While the
survey provided a brief description of what PrEP was, the
description did not provide information on potential side effects,
costs, efficacy or the need to maintain condom use, which could
influence willingness responses. It is also possible that participants
misunderstood PrEP with PEP, which is currently available and
for which a campaign in Scotland had been undertaken the
previous year [28]. However, the questionnaire explicitly stated
that PrEP was ‘different to PEP which is taken AFTER exposure,’
in an attempt to avoid this confusion.
This study has demonstrated a strong knowledge base and
interest in PrEP amongst MSM in Scotland. Findings indicate the
need to build on this interest and to consider the potentially
complex relationship between sexual risk behaviour, testing and
interest in PrEP. Age, HIV/STI testing and perceptions of risk are
factors that have been found to have a significant impact on PrEP
acceptability. It will be essential for these factors to be addressed
when considering for whom PrEP is best suited, and how access to
and use of PrEP will be best supported. Finally, it will also be
imperative to consider how risk might be managed with PrEP in
combination with other behavioural HIV prevention strategies if
and when PrEP becomes available in the UK.
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